Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery

Darolutamide improves progression-free survival across comorbidities in metastatic hormone-sensitive prostate cancer

225Ac-PSMA-trillium shows high PSA response and favourable safety in metastatic castration-resistant prostate cancer

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension

Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control

QoL outcomes are inconsistently reported in contemporary phase III genitourinary cancer trials

Cytoreductive SBRT with ipilimumab and nivolumab in de novo mRCC shows no PFS benefit but is safe

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC

ArteraAI MMAI enhances prediction of biochemical recurrence and metastasis in localised prostate cancer

Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows promising responses in metastatic clear cell RCC

ASCO GU 2026: Updates in renal cancer